DDR on DTC: Relpax

Share this article:
Deborah Dick-Rath
Deborah Dick-Rath

Relpax, the migraine drug from Pfizer, has just launched a DTC print campaign that is highly disconcerting. Although the drug is strategically positioned against Imitrex, that info is hard to find in the print ads that are currently appearing in general media magazines such as People. And while the Relpax creative team put in a valiant effort, in the end, they were defeated by too many typefaces, too much copy, too many messages and a somewhat unfortunate choice in art direction.

The golden rule of news, “Don't bury the lead,” should have been applied here. We're not sure what's most important for migraine sufferers to know about Relpax. Is it the comparison to Imitrex? The proof from two clinical trials? Or the sub-message, “Works fast and lasts?” None of these ideas “lead” the brand story.

DTC ads used to be over-aspirational—we saw relieved arthritis sufferers running marathons or playing Frisbee. With Relpax, the insight seems to be that sufferers just aspire to do such everyday activities as mopping the floor. The art direction insists on a literal interpretation, too. We see a black-and-white image of a woman crouching in agony, followed by a glowing orange-hued picture of her happily mopping. Clocks cleverly display the two hours difference from darkness to light.

We hope that Relpax is a success for Pfizer and that migraine sufferers find relief. We also hope they get (strictly aspirationally) excused from swabbing the deck.

Deborah Dick-Rath is the President of Epic Proportions, a Healthcare Communications Consultancy. She can be reached at deborahdrath@optonline.net
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?